In recent years, the AI pharmaceutical industry has been entering a prosperous golden period of development. With the rapid advancement of AI technology and the widespread application of big data, AI has shown tremendous potential and value in the field of drug development. The traditional drug development process is lengthy, costly, and has a high failure rate. The introduction of AI technology has made drug development more efficient and precise.
Medicilon, as a one-stop biopharmaceutical preclinical CRO, has been actively exploring cutting-edge technologies in drug development for twenty years. In the AI pharmaceutical field, Medicilon has established an AI drug discovery platform based on collaborations with several AI innovative drug development companies such as InSilico Medicine and MindRink.
Medicilon's AI technology service platform can provide protein structure prediction and simulation, binding site discovery, information extraction and cleansing, as well as customized project database construction, meeting diverse needs of researchers. In addition, the platform deeply supports key research and development stages such as Target-to-hit, Hit-to-lead, Lead-to-PCC, providing comprehensive technical support for drug development and accelerating the drug development pipeline process.
Medicilon has extensive research experience in structural biology, providing strong service support for Structure-Based Drug Design (SBDD).
Multiple protein expression systems
Various purification tool enzymes
Years of experience in expression and purification
High-throughput screening for crystallization conditions
Customized crystal cultivation
Collaboration with multiple partners
Application of open-source data models
Collaboration with multiple partners to provide more accurate predictions
Medicilon's AI Target Bioanalysis utilizes methods such as biological pathway analysis, omics analysis, and organ expression analysis to deeply explore the connections of biomarkers, uncovering potential drug targets. In addition, the platform collaborates closely with multiple virtual compound library suppliers to conduct efficient virtual screening, rapidly generating hit compounds, and verifying them through various technological methods.
Biological Pathway Analysis
AI-assisted construction of biological pathway databases
AI virtual analysis of biological pathway signal topology
Omics Analysis
Machine learning for exploring biomarker connections
Organ Expression Analysis
Discovery of expression sites by integrating big data with reality
(1) Deep collaboration with multiple virtual compound library suppliers (Enamine, Life chemicals)
(2) Efficient virtual screening
(3) Support for high-throughput screening methods such as TR-FRET, FP
(4) Rapid generation and derivatization of hit compounds
(5) Support for Hit validation using NMR, MST, SPR
From Hit to Lead compounds, Medicilon AI Drug Discovery Platform utilizes advanced AIDD/SBDD technologies to design novel scaffold molecules and optimize the structure and activity of drug molecules.
(1) AIDD/SBDD
(2) Novel scaffolds
(3) Molecular docking
(4) Molecular dynamics simulations
(5) Free energy perturbation
(6) Synthetic feasibility analysis
In the journey of drug development, optimizing lead compounds is a crucial step. Medicilon AI Drug Discovery Platform, leveraging its cutting-edge technology and extensive industry experience, provides comprehensive and precise support for lead compound optimization.
(1) AI molecular generation models
(2) AI activity prediction
(3) Structure-activity relationship (SAR) studies
(4) ADME prediction
(5) Physicochemical property prediction
(6) Selectivity/off-target activity
Regarding candidate compounds, Medicilon AI Drug Discovery Platform's services cover multiple critical stages including activity testing, animal efficacy validation, ensuring comprehensive validation and evaluation of candidate drugs before clinical application.
(1) Activity testing
(2) Animal efficacy validation
(3) Pharmacokinetic studies
(4) Toxicology studies
Relevant
news
marketing@medicilon.com
